Eli Lilly expands genetic medicine capabilities with Kelonia Therapeutics acquisition [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Eli Lilly and Co (NYSE:LLY) has agreed to acquire private clinical-stage biotechnology firm Kelonia Therapeutics in a deal aimed at expanding its capabilities in genetic medicines, the companies announced on Monday. The transaction centers on Kelonia's in vivo gene delivery platform, known as iGPS, which uses engineered lentiviral-based particles designed to modify T-cells inside the body. The approach is intended to enable the production of chimeric antigen receptor (CAR) T-cells without the need for the complex ex vivo manufacturing process typically associated with current CAR-T therapies. Kelonia's lead program, KLN-1010, is an investigational one-time intravenous therapy designed to generate anti-BCMA CAR-T cells in patients. It is currently being evaluated in a Phase 1 study for relapsed or refractory multiple myeloma, a blood cancer characterized by malignant plasma cells. Early clinical findings from the program were presented at the 2025 American Society of Hematology
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly (LLY): 3 Reasons We Love This Stock [Yahoo! Finance]Yahoo! Finance
- Will Eli Lilly's New GLP-1 Pill Get the Stock Get Back to a $1 Trillion Valuation? [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Will Eli Lilly's New GLP-1 Pill Get the Stock Get Back to a $1 Trillion Valuation? [Yahoo! Finance]Yahoo! Finance
- Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies [TheStreet.com]TheStreet.com
- Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapiesPR Newswire
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- LLY's page on the SEC website